Læknablaðið : fylgirit - 01.06.1982, Qupperneq 25

13
LOW-DOSE HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS
AFTER ACUTE MYOCARDIAL INFARCTION:
L.Remvig, S.Aa. Mortensen, O.S. Als, V.Mentzel and G. Holm.
Frederiksborg Amts Sygehus, Helsingör, Danmark
lo7 patients with acute myocardial infarction (Aí^I) completed
a randomized double-blind trial about the effect of sub-
cutaneous low-dose heparin against deep-vein thrombosis
diagnosed by 125 I-fibrinogen scanning (IFS)
The incidence of positive IFS was reduced from 14,3 % in the
placebo group (N= 56) to 5,9% in the^heparin group (N= 51).
The reduction was not significant (X with Yates correction:
2,o4, p>o,o5. The 95% confidence limits of the difference:
-2,8% - 19,6%).
The trial indicated an increased incidence of positive IFS
among placebo treated AMI-patients in the following risk
groups:> 7o years, left ventricular failure and immobili-
zation>48 hours. However among the heparin treated patients
immoblized for more than 48 hours the incidence of positive
IFS was still increased and now significantly increased.
A significant higher incidence of suggilations at the inject-
ion site was registered in the heparin group (p<o,ooo5).
Conclusion: Prophylaxis with subcutaneous low-dose heparin
against deep-vein thrombosis in patients with acute myocardial
infarction is not an alternative treatment to early
mobilization.